A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D [KOS 862] in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D [KOS 862] in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2008

At a glance

  • Drugs Epothilone D (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Sep 2008 Actual end date changed from 1 Oct 2002 to 1 Jun 2003 according to ClinicalTrials.gov.
    • 16 Sep 2008 Actual end date changed from 1 Oct 2002 to 1 Jun 2003 according to ClinicalTrials.gov.
    • 16 Sep 2008 Sponsor and collaborator changed from Kosan Biosciences to Bristol-Myers Squibb according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top